 At Week 32, if the Investigator considers it in the patients best interest patients will progress to the Maintenance Phase of the study and will continue to be dosed every 4 weeks or as close to this interval as permitted due to practical or logistical considerations. Patients will be followed up for assessment of safety, response to treatment, survival, and immunological markers for up to 4.5 years. 